Abstract
In a randomized, double-blind, placebo-controlled study beginning 4 weeks after uncomplicated acute myocardial infarction, it was established that the baseline plasma tissue factor antigen level was significantly higher in patients with myocardial infarction than in control subjects, and enalapril therapy significantly reduced the elevated plasma tissue factor antigen level. This may be associated with the reduction in the risk of coronary thrombosis seen with the use of angiotensin-converting enzyme inhibitors.
Publication types
-
Clinical Trial
-
Comparative Study
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Angiotensin-Converting Enzyme Inhibitors / pharmacology*
-
Angiotensin-Converting Enzyme Inhibitors / therapeutic use
-
Double-Blind Method
-
Drug Therapy, Combination
-
Enalapril / pharmacology*
-
Enalapril / therapeutic use
-
Enzyme-Linked Immunosorbent Assay / methods
-
Female
-
Humans
-
Male
-
Middle Aged
-
Myocardial Infarction / blood
-
Myocardial Infarction / drug therapy*
-
Peptidyl-Dipeptidase A / blood
-
Peptidyl-Dipeptidase A / drug effects
-
Thromboplastin / analysis
-
Thromboplastin / drug effects*
-
Time Factors
Substances
-
Angiotensin-Converting Enzyme Inhibitors
-
Enalapril
-
Thromboplastin
-
Peptidyl-Dipeptidase A